GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Eli Lilly has ... trials front Lilly announced plans to start a five-year real-world evidence study involving tirzepatide, the dual GIP/GLP-1 receptor agonist in the company's Mounjaro drug ...